BiotechTube

Trastuzumab + Paclitaxel + Epirubicin + Carboplatin

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER-2 Positive Breast Cancer

Conditions

HER-2 Positive Breast Cancer

Trial Timeline

Aug 1, 2011 → Feb 1, 2015

NCT ID
NCT01428414

About Trastuzumab + Paclitaxel + Epirubicin + Carboplatin

Trastuzumab + Paclitaxel + Epirubicin + Carboplatin is a phase 2 stage product being developed by Roche for HER-2 Positive Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01428414. Target conditions include HER-2 Positive Breast Cancer.

What happened to similar drugs?

0 of 2 similar drugs in HER-2 Positive Breast Cancer were approved

Approved (0) Terminated (0) Active (2)
🔄palbociclib + trastuzumab + pertuzumab + letrozole + Anastrozole + Exemestane + FulvestrantPfizerPhase 3
🔄Margetuximab + Trastuzumab + Physician's choice of chemotherapy.MacroGenicsPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01428414Phase 2UNKNOWN

Competing Products

11 competing products in HER-2 Positive Breast Cancer

See all competitors
ProductCompanyStageHype Score
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
31
eribulin + carboplatin + trastuzumabEisaiPhase 1/2
24
Apatinib and S-1Jiangsu Hengrui MedicinePhase 2
31
V930MerckPhase 1
29
Everolimus + Vinorelbine + TrastuzumabNovartisPhase 2
35
IV LBH589 + Oral LBH589 + trastuzumab + paclitaxelNovartisPhase 1
29
T-DM1RochePhase 2
35
palbociclib + trastuzumab + pertuzumab + letrozole + Anastrozole + Exemestane + FulvestrantPfizerPhase 3
44
Zumsemetinib + Capecitabine + Zoledronic acid + DenosumabUnited TherapeuticsPhase 1/2
36
Alisertib + Endocrine therapyPuma BiotechnologyPhase 2
32
Margetuximab + Trastuzumab + Physician's choice of chemotherapy.MacroGenicsPhase 3
30